$USNA
USANA Health Sciences Inc Stock $usna

$usna Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000143774921011680 Filed on May 11, 2021

Income Statement

Concept	2021 Q2	2020 Q1
Revenue	$308.0M	$266.6M
YoY Change	18.91%	-2.33%
Cost Of Revenue	$57.65M	$46.06M
YoY Change	20.93%	0.34%
Gross Profit	$250.3M	$220.6M
YoY Change	18.46%	-2.88%
Gross Profit Margin	81.28%	82.72%
Selling, General & Admin	$71.63M	$65.48M
YoY Change	17.66%	-5.86%
% of Gross Profit	28.62%	29.69%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$3.231M	$3.494M
YoY Change	-7.69%	-9.62%
% of Gross Profit	1.29%	1.58%
Operating Expenses	$206.1M	$181.5M
YoY Change	20.03%	-5.49%
Operating Profit	$44.20M	$39.01M
YoY Change	11.65%	11.45%
Interest Expense	$5.000K	$21.00K
YoY Change	-97.7%	75.0%
% of Operating Profit	0.01%	0.05%
Other Income/Expense, Net	$139.0K	$151.0K
YoY Change	-64.63%	-88.29%
Pretax Income	$44.34M	$39.16M
YoY Change	10.9%	7.9%
Income Tax	$13.72M	$12.61M
% Of Pretax Income	30.93%	32.2%
Net Earnings	$30.62M	$26.55M
YoY Change	9.45%	9.85%
Net Earnings / Revenue	9.94%	9.96%
Basic Earnings Per Share	$1.47	$1.24
Diluted Earnings Per Share	$1.45	$1.23
COMMON SHARES
Basic Shares Outstanding	20.89M	21.50M
Diluted Shares Outstanding	21.10M	21.55M

Balance Sheet

Concept	2021 Q2	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$257.0M	$194.1M
YoY Change	13.02%	-22.95%
Cash & Equivalents	$257.0M	$194.1M
Short-Term Investments
Other Short-Term Assets	$28.60M	$32.10M
YoY Change	1.06%	0.94%
Inventory	$87.65M	$60.57M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$373.2M	$286.8M
YoY Change	14.84%	-22.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$98.62M	$97.25M
YoY Change	0.19%	5.71%
Goodwill	$17.31M	$16.49M
YoY Change	4.78%	-3.4%
Intangibles	$30.35M	$29.07M
YoY Change	4.61%	-9.79%
Long-Term Investments
YoY Change
Other Assets	$59.89M	$41.42M
YoY Change	51.63%	12.37%
Total Long-Term Assets	$211.3M	$187.0M
YoY Change	12.89%	3.08%
TOTAL ASSETS
Total Short-Term Assets	$373.2M	$286.8M
Total Long-Term Assets	$211.3M	$187.0M
Total Assets	$584.5M	$473.8M
YoY Change	14.13%	-14.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.95M	$11.82M
YoY Change	9.23%	1.06%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$151.5M	$124.5M
YoY Change	8.4%	-4.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$16.31M	$17.91M
YoY Change	-2.78%	39.18%
Total Long-Term Liabilities	$16.31M	$17.91M
YoY Change	-2.78%	39.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$151.5M	$124.5M
Total Long-Term Liabilities	$16.31M	$17.91M
Total Liabilities	$167.8M	$142.4M
YoY Change	7.2%	-0.31%
SHAREHOLDERS EQUITY
Retained Earnings	$353.2M	$284.7M
YoY Change	12.97%	-13.47%
Common Stock	$54.10M	$52.03M
YoY Change	-2.6%	-24.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$402.8M	$317.6M
YoY Change
Total Liabilities & Shareholders Equity	$584.5M	$473.8M
YoY Change	14.13%	-14.11%

Cashflow Statement

Concept	2021 Q2	2020 Q1
OPERATING ACTIVITIES
Net Income	$30.62M	$26.55M
YoY Change	9.45%	9.85%
Depreciation, Depletion And Amortization	$3.231M	$3.494M
YoY Change	-7.69%	-9.62%
Cash From Operating Activities	$19.66M	$30.79M
YoY Change	-39.7%	457.62%
INVESTING ACTIVITIES
Capital Expenditures	$1.597M	$7.266M
YoY Change	-145.63%	181.96%
Acquisitions
YoY Change
Other Investing Activities	-$1.500M	-$1.000M
YoY Change	-175.0%	-102.85%
Cash From Investing Activities	-$3.088M	-$8.270M
YoY Change	105.87%	-125.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$67.61M	$57.03M
YoY Change		90.1%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$70.48M	-$58.85M
YoY Change		87.35%
NET CHANGE
Cash From Operating Activities	$19.66M	$30.79M
Cash From Investing Activities	-$3.088M	-$8.270M
Cash From Financing Activities	-$70.48M	-$58.85M
Net Change In Cash	-$55.87M	-$40.77M
YoY Change	-279.63%	-477.97%
FREE CASH FLOW
Cash From Operating Activities	$19.66M	$30.79M
Capital Expenditures	$1.597M	$7.266M
Free Cash Flow	$18.06M	$23.52M
YoY Change	-49.97%	698.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20236693
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Inventory Net InventoryNet	90224000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28570000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23145000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	373180000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	425286000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	98622000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	100445000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	17310000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	402777000	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20422000
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20422000
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21038000
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21038000
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	584512000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	640887000	USD
CY2021Q1	usna	Nonfinancial Assets Fair Value Disclosure NonfinancialAssetsFairValueDisclosure	0	USD
CY2021	usna	Equity Securities Without Readily Determinable Fair Value Price Adjustment Cumulative Amount EquitySecuritiesWithoutReadilyDeterminableFairValuePriceAdjustmentCumulativeAmount	0	USD
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	256964000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	311917000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	87646000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	17367000	USD
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	30345000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	30796000	USD
CY2021Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	5164000	USD
CY2021Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	4640000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	59891000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	62353000	USD
CY2021Q2	us-gaap	Assets Assets	584512000	USD
CY2021Q1	us-gaap	Assets Assets	640887000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11952000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	18195000	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	139500000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	149878000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	151452000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	168073000	USD
CY2021Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	13975000	USD
CY2021Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12009000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16308000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	19155000	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	21000	USD
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	54084000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	62460000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	353213000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	382794000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4540000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3625000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	441650000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	307976000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	266619000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	57651000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	46059000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	250325000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	220560000	USD
CY2021Q2	usna	Associate Incentives AssociateIncentives	134495000	USD
CY2020Q1	usna	Associate Incentives AssociateIncentives	116069000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71633000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	65479000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	206128000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	181548000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	44197000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	39012000	USD
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	760000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	984000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	5000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	21000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-616000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-812000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	139000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	151000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	44336000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	39163000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13715000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12611000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	30621000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	26552000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.47
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.24
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.45
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.23
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20892000
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21497000
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21096000
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21551000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	30621000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	26552000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-2531000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-6237000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1616000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1039000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-915000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5198000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	29706000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	21354000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	351712000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	26552000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5198000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3394000	USD
CY2020Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	57029000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19659000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	30786000	USD
CY2021Q2	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	51000	USD
CY2020Q1	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	85000	USD
CY2020Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1823000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	317608000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	441650000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	30621000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-915000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3740000	USD
CY2021Q2	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	69454000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	USD
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2865000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	402777000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	30621000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	26552000	USD
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3231000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3494000	USD
CY2021Q2	usna	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	2259000	USD
CY2020Q1	usna	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	2255000	USD
CY2021Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-47000	USD
CY2020Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	USD
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	3740000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3394000	USD
CY2021Q2	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	2968000	USD
CY2020Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	4611000	USD
CY2021Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1393000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5153000	USD
CY2021Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3960000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4262000	USD
CY2021Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6899000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-174000	USD
CY2021Q2	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-13741000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-10237000	USD
CY2021Q2	us-gaap	Payments For Hedge Investing Activities PaymentsForHedgeInvestingActivities	1555000	USD
CY2020Q1	us-gaap	Payments For Hedge Investing Activities PaymentsForHedgeInvestingActivities	1089000	USD
CY2021Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	13000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2021Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1597000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7266000	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3088000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8270000	USD
CY2021Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	67610000	USD
CY2020Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	57029000	USD
CY2021Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2865000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1823000	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-70475000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-58852000	USD
CY2021Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1962000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-4436000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-55866000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40772000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	315937000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	237688000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	260071000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	196916000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	256964000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	194098000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	260071000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	196916000	USD
CY2021Q2	us-gaap	Interest Paid Net InterestPaidNet	3000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	2000	USD
CY2021Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	13523000	USD
CY2020Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	9694000	USD
CY2021Q2	usna	Noncashrightofuseassetobtainedinexchangeforoperatingleaseliability Noncashrightofuseassetobtainedinexchangeforoperatingleaseliability	829000	USD
CY2020Q1	usna	Noncashrightofuseassetobtainedinexchangeforoperatingleaseliability Noncashrightofuseassetobtainedinexchangeforoperatingleaseliability	1914000	USD
CY2021Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	239000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	608000	USD
CY2021Q2	usna	Unsettled Trades For Repurchase Of Common Stock UnsettledTradesForRepurchaseOfCommonStock	1844000	USD
CY2020Q1	usna	Unsettled Trades For Repurchase Of Common Stock UnsettledTradesForRepurchaseOfCommonStock	0	USD
CY2021Q2	usna	Nonfinancial Assets Fair Value Disclosure NonfinancialAssetsFairValueDisclosure	0	USD
CY2021Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	27165000	USD
CY2021Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	28328000	USD
CY2021Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10181000	USD
CY2021Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9956000	USD
CY2021Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	50300000	USD
CY2021Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	51940000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	87646000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	90224000	USD
CY2021Q2	usna	Equity Securities Without Readily Determinable Fair Value Price Adjustment Cumulative Amount EquitySecuritiesWithoutReadilyDeterminableFairValuePriceAdjustmentCumulativeAmount	0	USD
CY2021Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	USD
CY2021Q2	us-gaap	Other Income OtherIncome	972000	USD
CY2020Q1	us-gaap	Other Income OtherIncome	643000	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15952000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	13852000	USD
CY2021Q2	usna	Contract With Customer Liability Increase Decrease In Deferred Revenue ContractWithCustomerLiabilityIncreaseDecreaseInDeferredRevenue	16017000	USD
CY2021	usna	Contract With Customer Liability Increase Decrease In Deferred Revenue ContractWithCustomerLiabilityIncreaseDecreaseInDeferredRevenue	15952000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	15198000	USD
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	13852000	USD
CY2021Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16771000	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15952000	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	30621000	USD
CY2021Q2	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	98684000	USD
CY2020Q1	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	90000000	USD
CY2021Q2	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	190000	USD
CY2020Q1	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	850000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	26552000	USD
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20892000
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21497000
CY2021Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	204000
CY2020Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	54000
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21096000
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21551000
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.47
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.24
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.45
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.23
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	57000
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	815000
CY2021Q2	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	721000
CY2020Q1	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	785000
CY2021Q2	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	69454000	USD
CY2020Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	57029000	USD
CY2021Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	80546000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	307976000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	266619000	USD

Files In Submission

Name	View Source	Status
0001437749-21-011680-index-headers.html	Edgar Link	pending
0001437749-21-011680-index.html	Edgar Link	pending
0001437749-21-011680.txt	Edgar Link	pending
0001437749-21-011680-xbrl.zip	Edgar Link	pending
ex_239003.htm	Edgar Link	pending
ex_239004.htm	Edgar Link	pending
ex_239005.htm	Edgar Link	pending
ex_239006.htm	Edgar Link	pending
ex_248440.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
usna-20210403.xsd	Edgar Link	pending
usna-20210403_cal.xml	Edgar Link	unprocessable
usna-20210403_def.xml	Edgar Link	unprocessable
usna-20210403_lab.xml	Edgar Link	unprocessable
usna-20210403_pre.xml	Edgar Link	unprocessable
usna20210402_10q.htm	Edgar Link	pending
usna20210402_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$USNA
USANA Health Sciences Inc Stock $usna

2021 Q2 Form 10-Q Financial Statement

#000143774921011680 Filed on May 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USNA USANA Health Sciences Inc Stock $usna

2021 Q2 Form 10-Q Financial Statement

#000143774921011680 Filed on May 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USNA
USANA Health Sciences Inc Stock $usna